Integra Lifesciences Holdings Corp (NASDAQ:IART) is Tributary Capital Management LLC’s 5th Largest Position

Tributary Capital Management LLC raised its stake in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 30.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 508,838 shares of the life sciences company’s stock after purchasing an additional 119,592 shares during the quarter. Integra Lifesciences makes up about 2.1% of Tributary Capital Management LLC’s portfolio, making the stock its 5th biggest holding. Tributary Capital Management LLC owned 0.60% of Integra Lifesciences worth $28,352,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of IART. Bank of New York Mellon Corp grew its stake in Integra Lifesciences by 1.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 751,700 shares of the life sciences company’s stock valued at $49,514,000 after acquiring an additional 7,547 shares during the last quarter. Credit Suisse AG boosted its stake in shares of Integra Lifesciences by 19.6% during the 3rd quarter. Credit Suisse AG now owns 56,858 shares of the life sciences company’s stock worth $3,745,000 after purchasing an additional 9,309 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Integra Lifesciences by 104.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,064 shares of the life sciences company’s stock worth $18,251,000 after purchasing an additional 141,368 shares during the last quarter. Riverhead Capital Management LLC boosted its stake in shares of Integra Lifesciences by 35.0% during the 3rd quarter. Riverhead Capital Management LLC now owns 4,626 shares of the life sciences company’s stock worth $305,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Integra Lifesciences by 549.3% during the 3rd quarter. Renaissance Technologies LLC now owns 358,160 shares of the life sciences company’s stock worth $23,592,000 after purchasing an additional 303,000 shares during the last quarter. Hedge funds and other institutional investors own 84.56% of the company’s stock.

Shares of IART stock opened at $52.81 on Friday. The stock has a market cap of $4.51 billion, a PE ratio of 21.82, a P/E/G ratio of 1.53 and a beta of 0.90. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $67.50. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.86 and a current ratio of 2.86.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The business had revenue of $359.69 million for the quarter, compared to analyst estimates of $361.12 million. During the same period in the prior year, the firm posted $0.58 EPS. The company’s revenue was up .7% on a year-over-year basis. Analysts forecast that Integra Lifesciences Holdings Corp will post 2.7 earnings per share for the current fiscal year.

Several research firms have issued reports on IART. ValuEngine cut shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Thursday, April 18th. Zacks Investment Research raised shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research note on Thursday. BidaskClub cut shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Finally, Oppenheimer cut their price objective on shares of Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. Integra Lifesciences has a consensus rating of “Hold” and an average target price of $59.42.

In other news, major shareholder Richard E. Caruso sold 30,128 shares of Integra Lifesciences stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $56.06, for a total transaction of $1,688,975.68. Following the sale, the insider now owns 143,384 shares in the company, valued at $8,038,107.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lisa Evoli sold 1,291 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $55.90, for a total transaction of $72,166.90. Following the sale, the insider now directly owns 4,968 shares of the company’s stock, valued at approximately $277,711.20. The disclosure for this sale can be found here. Company insiders own 4.50% of the company’s stock.

WARNING: “Integra Lifesciences Holdings Corp (NASDAQ:IART) is Tributary Capital Management LLC’s 5th Largest Position” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/integra-lifesciences-holdings-corp-iart-position-increased-by-tributary-capital-management-llc.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.